Pre-order Enquiry
Request Free Sample
Global Benign Prostatic Hyperplasia (BPH) Drugs Market Report, History and Forecast 2015-2026, Breakdown Data by Manufacturers, Key Regions, Types and Application
SKU ID : QYR-16240354 | Publishing Date : 24-Aug-2020
Request Sample
Request Customization
Check DiscountsDetailed TOC of Global Benign Prostatic Hyperplasia (BPH) Drugs Market Report, History and Forecast 2015-2026, Breakdown Data by Manufacturers, Key Regions, Types and Application
1 Benign Prostatic Hyperplasia (BPH) Drugs Market Overview1.1 Benign Prostatic Hyperplasia (BPH) Drugs Product Overview
1.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Segment by Type
1.2.1 Alpha-Blocker
1.2.2 Phosphodiesterase Type-5 Inhibitors
1.2.3 Others
1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type (2015-2026)
1.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Overview by Type (2015-2026)
1.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Size Review by Type (2015-2020)
1.3.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Breakdown by Type (2015-2026)
1.3.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Breakdown by Type (2015-2026)
1.3.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Selling Price (ASP) by Type (2015-2026)
1.3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Type (2021-2026)
1.3.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Breakdown by Application (2021-2026)
1.3.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Breakdown by Application (2021-2026)
1.3.3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Selling Price (ASP) by Application (2021-2026)
1.4 Key Regions Market Size Segment by Type (2015-2020)
1.4.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2015-2026)
1.4.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2015-2026)
1.4.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2015-2026)
1.4.4 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2015-2026)
1.4.5 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2015-2026)
2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Competition by Company
2.1 Global Top Players by Benign Prostatic Hyperplasia (BPH) Drugs Sales (2015-2020)
2.2 Global Top Players by Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2015-2020)
2.3 Global Top Players Benign Prostatic Hyperplasia (BPH) Drugs Average Selling Price (ASP) (2015-2020)
2.4 Global Top Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Benign Prostatic Hyperplasia (BPH) Drugs Market Competitive Situation and Trends
2.5.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Concentration Rate (2015-2020)
2.5.2 Global 5 and 10 Largest Manufacturers by Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue in 2019
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Drugs as of 2019)
2.7 Date of Key Manufacturers Enter into Benign Prostatic Hyperplasia (BPH) Drugs Market
2.8 Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Global Benign Prostatic Hyperplasia (BPH) Drugs Status and Outlook by Region (2015-2026)
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size and CAGR by Region: 2015 VS 2020 VS 2026
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Market Share by Region (2015-2020)
3.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2015-2020)
3.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2015-2020)
3.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2015-2020)
3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Market Share by Region (2021-2026)
3.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2021-2026)
3.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2021-2026)
3.3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
3.4 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
3.4.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue YoY Growth (2015-2026)
3.4.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY Growth (2015-2026)
3.5 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
3.5.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue YoY Growth (2015-2026)
3.5.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY Growth (2015-2026)
3.6 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
3.6.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue YoY Growth (2015-2026)
3.6.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY Growth (2015-2026)
3.7 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
3.7.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue YoY Growth (2015-2026)
3.7.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY Growth (2015-2026)
3.8 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
3.8.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue YoY Growth (2015-2026)
3.8.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY Growth (2015-2026)
4 Global Benign Prostatic Hyperplasia (BPH) Drugs by Application
4.1 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application
4.1.1 Hospitals
4.1.2 Drugstores
4.1.3 Others
4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application: 2015 VS 2020 VS 2026
4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Sales by Application (2015-2020)
4.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Sales by Application (2021-2026)
4.5 Key Regions Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
4.5.1 North America Benign Prostatic Hyperplasia (BPH) Drugs by Application
4.5.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs by Application
4.5.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs by Application
4.5.4 Latin America Benign Prostatic Hyperplasia (BPH) Drugs by Application
4.5.5 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs by Application
5 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country (2015-2026)
5.1 North America Market Size Market Share by Country (2015-2020)
5.1.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2015-2020)
5.1.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2015-2020)
5.2 North America Market Size Market Share by Country (2021-2026)
5.2.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2021-2026)
5.2.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2021-2026)
5.3 North America Market Size YoY Growth by Country
5.3.1 U.S. Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
5.3.2 Canada Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
6 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country (2015-2026)
6.1 Europe Market Size Market Share by Country (2015-2020)
6.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2015-2020)
6.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2015-2020)
6.2 Europe Market Size Market Share by Country (2021-2026)
6.2.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2021-2026)
6.2.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2021-2026)
6.3 Europe Market Size YoY Growth by Country
6.3.1 Germany Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
6.3.2 France Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
6.3.3 U.K. Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
6.3.4 Italy Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
6.3.5 Russia Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
7 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country (2015-2026)
7.1 Asia-Pacific Market Size Market Share by Country (2015-2020)
7.1.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2015-2020)
7.1.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2015-2020)
7.2 Asia-Pacific Market Size Market Share by Country (2021-2026)
7.2.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2021-2026)
7.2.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2021-2026)
7.3 Asia-Pacific Market Size YoY Growth by Country
7.3.1 China Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
7.3.2 Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
7.3.3 South Korea Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
7.3.4 India Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
7.3.5 Australia Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
7.3.6 Taiwan Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
7.3.7 Indonesia Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
7.3.8 Thailand Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
7.3.9 Malaysia Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
7.3.10 Philippines Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
7.3.11 Vietnam Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
8 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country (2015-2026)
8.1 Latin America Market Size Market Share by Country (2015-2020)
8.1.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2015-2020)
8.1.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2015-2020)
8.2 Latin America Market Size Market Share by Country (2021-2026)
8.2.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2021-2026)
8.2.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2021-2026)
8.3 Latin America Market Size YoY Growth by Country
8.3.1 Mexico Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
8.3.2 Brazil Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
8.3.3 Argentina Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
9 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country (2015-2026)
9.1 Middle East and Africa Market Size Market Share by Country (2015-2020)
9.1.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2015-2020)
9.1.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2015-2020)
9.2 Middle East and Africa Market Size Market Share by Country (2021-2026)
9.2.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2021-2026)
9.2.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2021-2026)
9.3 Middle East and Africa Market Size YoY Growth by Country
9.3.1 Turkey Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
9.3.2 Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
9.3.3 UAE Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth (2015-2026)
10 Company Profiles and Key Figures in Benign Prostatic Hyperplasia (BPH) Drugs Business
10.1 Eli Lilly
10.1.1 Eli Lilly Corporation Information
10.1.2 Eli Lilly Description, Business Overview and Total Revenue
10.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
10.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
10.1.5 Eli Lilly Recent Development
10.2 GlaxoSmithKline
10.2.1 GlaxoSmithKline Corporation Information
10.2.2 GlaxoSmithKline Description, Business Overview and Total Revenue
10.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
10.2.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
10.2.5 GlaxoSmithKline Recent Development
10.3 Astellas Pharma
10.3.1 Astellas Pharma Corporation Information
10.3.2 Astellas Pharma Description, Business Overview and Total Revenue
10.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
10.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
10.3.5 Astellas Pharma Recent Development
10.4 Sanofi
10.4.1 Sanofi Corporation Information
10.4.2 Sanofi Description, Business Overview and Total Revenue
10.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
10.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
10.4.5 Sanofi Recent Development
10.5 Pfizer
10.5.1 Pfizer Corporation Information
10.5.2 Pfizer Description, Business Overview and Total Revenue
10.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
10.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
10.5.5 Pfizer Recent Development
10.6 Abbott
10.6.1 Abbott Corporation Information
10.6.2 Abbott Description, Business Overview and Total Revenue
10.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
10.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
10.6.5 Abbott Recent Development
10.7 Allergan
10.7.1 Allergan Corporation Information
10.7.2 Allergan Description, Business Overview and Total Revenue
10.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
10.7.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
10.7.5 Allergan Recent Development
10.8 TEVA
10.8.1 TEVA Corporation Information
10.8.2 TEVA Description, Business Overview and Total Revenue
10.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
10.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
10.8.5 TEVA Recent Development
10.9 Mylan
10.9.1 Mylan Corporation Information
10.9.2 Mylan Description, Business Overview and Total Revenue
10.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
10.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
10.9.5 Mylan Recent Development
10.10 Novartis
10.10.1 Company Basic Information, Manufacturing Base and Competitors
10.10.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification
10.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2015-2020)
10.10.4 Main Business Overview
10.10.5 Novartis Recent Development
10.11 Merck
10.11.1 Merck Corporation Information
10.11.2 Merck Description, Business Overview and Total Revenue
10.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
10.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
10.11.5 Merck Recent Development
11 Benign Prostatic Hyperplasia (BPH) Drugs Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis
11.4 Market Opportunities, Challenges, Risks and Influences Factors Analysis
11.4.1 Industry Trends
11.4.2 Market Drivers
11.4.3 Market Challenges
11.4.4 Porter’s Five Forces Analysis
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Distributors
12.3 Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology/Research Approach
14.1.1 Research Programs/Design
14.1.2 Market Size Estimation
14.1.3 Market Breakdown and Data Triangulation
14.2 Data Source
14.2.1 Secondary Sources
14.2.2 Primary Sources
14.3 Author Details
14.4 Disclaimer
List of Figures, Tables and Charts Available in Global Benign Prostatic Hyperplasia (BPH) Drugs Market Report, History and Forecast 2015-2026, Breakdown Data by Manufacturers, Key Regions, Types and Application
List of TablesTable 1. Major Players of Alpha-Blocker
Table 2. Major Players of Phosphodiesterase Type-5 Inhibitors
Table 3. Major Players of Others
Table 4. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Potential by Type: CAGR (2020-2026) (US$ Million)
Table 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Type (2015-2020) (M Units)
Table 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2015-2020)
Table 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) by Type (2015-2020)
Table 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2015-2020)
Table 9. Global Benign Prostatic Hyperplasia (BPH) Drugs Average Selling Price (ASP) (US$/Unit) by Type (2015-2020)
Table 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2026) (M Units)
Table 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2021-2026)
Table 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Type (2021-2026)
Table 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2021-2026)
Table 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Average Selling Price (ASP) (US$/Unit) by Type (2021-2026)
Table 15. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales (US$/Unit) by Type (2015-2020)
Table 16. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales (US$/Unit) by Type (2015-2020)
Table 17. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales (US$/Unit) by Type (2015-2020)
Table 18. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales (US$/Unit) by Type (2015-2020)
Table 19. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales (US$/Unit) by Type (2015-2020)
Table 20. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Company (2015-2020)
Table 21. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Company (2015-2020)
Table 22. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million US$) by Company (2015-2020)
Table 23. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Company (2015-2020)
Table 24. Global Market Benign Prostatic Hyperplasia (BPH) Drugs Average Selling Price (US$/Unit) by Company (2015-2020)
Table 25. Global Benign Prostatic Hyperplasia (BPH) Drugs Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Top Manufacturers Product Category
Table 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Drugs as of 2019
Table 29. Date of Key Manufacturers Enter into Benign Prostatic Hyperplasia (BPH) Drugs Market
Table 30. Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Type
Table 31. Mergers & Acquisitions, Expansion Plans
Table 32. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Comparison by Region (2015-2026) (US$ Million): 2015 VS 2020 VS 2026
Table 33. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Region (2015-2020)
Table 34. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2015-2020)
Table 35. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Region (2015-2020)
Table 36. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2015-2020)
Table 37. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2015-2020)
Table 38. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Region (2021-2026)
Table 39. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2021-2026)
Table 40. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Region (2021-2026)
Table 41. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2021-2026)
Table 42. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 43. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application: 2015 VS 2020 VS 2026
Table 44. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application (2015-2020)
Table 45. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2015-2020)
Table 46. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application (2021-2026)
Table 47. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2021-2026)
Table 48. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application (2015-2020)
Table 49. North America Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application (2015-2020)
Table 50. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application (2015-2020)
Table 51. Europe Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application In 2019
Table 52. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application (2015-2020)
Table 53. Asia-Pacific Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application In 2019
Table 54. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application (2015-2020)
Table 55. Latin America Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application In 2019
Table 56. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application (2015-2020)
Table 57. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2015-2020)
Table 58. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Country (2015-2020)
Table 59. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2015-2020)
Table 60. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Country (2015-2020)
Table 61. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2015-2020)
Table 62. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Country (2021-2026)
Table 63. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2021-2026)
Table 64. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Country (2021-2026)
Table 65. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2021-2026)
Table 66. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Country (2015-2020)
Table 67. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2015-2020)
Table 68. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Country (2015-2020)
Table 69. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2015-2020)
Table 70. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Country (2021-2026)
Table 71. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2021-2026)
Table 72. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Country (2021-2026)
Table 73. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2021-2026)
Table 74. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Region (2015-2020)
Table 75. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2015-2020)
Table 76. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Region (2015-2020)
Table 77. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2015-2020)
Table 78. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Region (2021-2026)
Table 79. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2021-2026)
Table 80. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Region (2021-2026)
Table 81. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2021-2026)
Table 82. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Country (2015-2020)
Table 83. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2015-2020)
Table 84. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Country (2015-2020)
Table 85. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2015-2020)
Table 86. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Country (2021-2026)
Table 87. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2021-2026)
Table 88. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Country (2021-2026)
Table 89. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2021-2026)
Table 90. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Country (2015-2020)
Table 91. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2015-2020)
Table 92. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Country (2015-2020)
Table 93. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2015-2020)
Table 94. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Country (2021-2026)
Table 95. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2021-2026)
Table 96. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Country (2021-2026)
Table 97. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2021-2026)
Table 98. Eli Lilly Corporation Information
Table 99. Eli Lilly Description and Business Overview
Table 100. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 101. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 102. Eli Lilly Recent Development
Table 103. GlaxoSmithKline Corporation Information
Table 104. GlaxoSmithKline Description and Business Overview
Table 105. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 106. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 107. GlaxoSmithKline Recent Development
Table 108. Astellas Pharma Corporation Information
Table 109. Astellas Pharma Description and Business Overview
Table 110. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 111. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 112. Astellas Pharma Recent Development
Table 113. Sanofi Corporation Information
Table 114. Sanofi Description and Business Overview
Table 115. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 116. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 117. Sanofi Recent Development
Table 118. Pfizer Corporation Information
Table 119. Pfizer Description and Business Overview
Table 120. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 121. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 122. Pfizer Recent Development
Table 123. Abbott Corporation Information
Table 124. Abbott Description and Business Overview
Table 125. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 126. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 127. Abbott Recent Development
Table 128. Allergan Corporation Information
Table 129. Allergan Description and Business Overview
Table 130. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 131. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 132. Allergan Recent Development
Table 133. TEVA Corporation Information
Table 134. TEVA Description and Business Overview
Table 135. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 136. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 137. TEVA Recent Development
Table 138. Mylan Corporation Information
Table 139. Mylan Description and Business Overview
Table 140. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 141. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 142. Mylan Recent Development
Table 143. Novartis Corporation Information
Table 144. Novartis Description and Business Overview
Table 145. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 146. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 147. Novartis Recent Development
Table 148. Merck Corporation Information
Table 149. Merck Description and Business Overview
Table 150. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 151. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 152. Merck Recent Development
Table 153. Key Raw Materials Lists
Table 154. Raw Materials Key Suppliers Lists
Table 155. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 156. Key Challenges
Table 157. Market Risks
Table 158. Distributors List
Table 159. Benign Prostatic Hyperplasia (BPH) Drugs Downstream Customers
Table 160. Research Programs/Design for This Report
Table 161. Key Data Information from Secondary Sources
Table 162. Key Data Information from Primary Sources
List of Figures
Figure 1. Benign Prostatic Hyperplasia (BPH) Drugs Product Picture
Figure 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) Status and Outlook (2015-2026)
Figure 3. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Status and Outlook (2015-2026)
Figure 4. Product Picture of Alpha-Blocker
Figure 5. Global Alpha-Blocker Sales (M Units) and Growth Rate (2015-2020)
Figure 6. Product Picture of Phosphodiesterase Type-5 Inhibitors
Figure 7. Global Phosphodiesterase Type-5 Inhibitors Sales (M Units) and Growth Rate (2015-2020)
Figure 8. Product Picture of Others
Figure 9. Global Others Sales (M Units) and Growth Rate (2015-2020)
Figure 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate by Type (US$ Million)
Figure 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2015-2020)
Figure 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2019
Figure 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2015-2020)
Figure 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type in 2019
Figure 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2021-2026)
Figure 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type In 2019
Figure 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2021-2026)
Figure 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type In 2019
Figure 19. The 5 and 10 Largest Manufacturers in the World: Market Share by Benign Prostatic Hyperplasia (BPH) Drugs Sales in 2019
Figure 20. The 5 and 10 Largest Manufacturers in the World: Market Share by Benign Prostatic Hyperplasia (BPH) Drugs Revenue in 2019
Figure 21. Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) and Growth Rate (2015-2026)
Figure 23. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY Growth (2015-2026) (M Units)
Figure 24. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) and Growth Rate (2015-2026)
Figure 25. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY Growth (2015-2026) (M Units)
Figure 26. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) and Growth Rate (2015-2026)
Figure 27. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY Growth (2015-2026) (M Units)
Figure 28. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) and Growth Rate (2015-2026)
Figure 29. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY Growth (2015-2026) (M Units)
Figure 30. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) and Growth Rate (2015-2026)
Figure 31. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY Growth (2015-2026) (M Units)
Figure 32. Hospitals Examples
Figure 33. Drugstores Examples
Figure 34. Others Examples
Figure 35. U.S. Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) (2015-2026)
Figure 36. U.S. Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) (2015-2026)
Figure 37. Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) (2015-2026)
Figure 38. Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) (2015-2026)
Figure 39. Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) (2015-2026)
Figure 40. Germany Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) (2015-2026)
Figure 41. France Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) (2015-2026)
Figure 42. France Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) (2015-2026)
Figure 43. U.K. Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) (2015-2026)
Figure 44. U.K. Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) (2015-2026)
Figure 45. Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) (2015-2026)
Figure 46. Italy Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) (2015-2026)
Figure 47. Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) (2015-2026)
Figure 48. Russia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) (2015-2026)
Figure 49. China Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) (2015-2026)
Figure 50. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) (2015-2026)
Figure 51. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) (2015-2026)
Figure 52. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) (2015-2026)
Figure 53. South Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) (2015-2026)
Figure 54. South Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) (2015-2026)
Figure 55. India Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) (2015-2026)
Figure 56. India Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) (2015-2026)
Figure 57. Australia Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) (2015-2026)
Figure 58. Australia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) (2015-2026)
Figure 59. Taiwan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) (2015-2026)
Figure 60. Taiwan Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) (2015-2026)
Figure 61. Indonesia Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) (2015-2026)
Figure 62. Indonesia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) (2015-2026)
Figure 63. Thailand Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) (2015-2026)
Figure 64. Thailand Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) (2015-2026)
Figure 65. Malaysia Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) (2015-2026)
Figure 66. Malaysia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) (2015-2026)
Figure 67. Philippines Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) (2015-2026)
Figure 68. Philippines Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) (2015-2026)
Figure 69. Vietnam Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) (2015-2026)
Figure 70. Vietnam Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) (2015-2026)
Figure 71. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) (2015-2026)
Figure 72. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) (2015-2026)
Figure 73. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) (2015-2026)
Figure 74. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) (2015-2026)
Figure 75. Argentina Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) (2015-2026)
Figure 76. Argentina Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) (2015-2026)
Figure 77. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) (2015-2026)
Figure 78. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) (2015-2026)
Figure 79. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) (2015-2026)
Figure 80. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) (2015-2026)
Figure 81. UAE Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) (2015-2026)
Figure 82. UAE Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) (2015-2026)
Figure 83. Eli Lilly Total Revenue (US$ Million): 2019 Compared with 2018
Figure 84. GlaxoSmithKline Total Revenue (US$ Million): 2019 Compared with 2018
Figure 85. Astellas Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 86. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 87. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 88. Abbott Total Revenue (US$ Million): 2019 Compared with 2018
Figure 89. Allergan Total Revenue (US$ Million): 2019 Compared with 2018
Figure 90. TEVA Total Revenue (US$ Million): 2019 Compared with 2018
Figure 91. Mylan Total Revenue (US$ Million): 2019 Compared with 2018
Figure 92. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 93. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 94. Key Raw Materials Price
Figure 95. Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Cost Structure
Figure 96. Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis
Figure 97. Porter's Five Forces Analysis
Figure 98. Channels of Distribution
Figure 99. Distributors Profiles
Figure 100. Bottom-up and Top-down Approaches for This Report
Figure 101. Data Triangulation
Figure 102. Key Executives Interviewed
Keyplayers in Global Benign Prostatic Hyperplasia (BPH) Drugs Market Report, History and Forecast 2015-2026, Breakdown Data by Manufacturers, Key Regions, Types and Application
Eli LillyGlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Mylan
Novartis
Merck
